EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Evolus's Enterprise Value is $880.6 Mil.
Evolus's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-25.9 Mil. Therefore, Evolus's EV-to-FCF for today is -33.93.
The historical rank and industry rank for Evolus's EV-to-FCF or its related term are showing as below:
EOLS'
s EV-to-FCF Range Over the Past 10 Years
Min: -55.74 Med: -7.2 Max: -0.8
Current: -33.93
During the past 9 years, the highest EV-to-FCF of Evolus was -0.80. The lowest was -55.74. And the median was -7.20.
EOLS's EV-to-FCF is ranked worse than 100% of 520
companies
in the Drug Manufacturers industry
Industry Median: 25.045
vs EOLS: -33.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-21), Evolus's stock price is $13.42.
Evolus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.040. Therefore, Evolus's PE Ratio for today is At Loss.
Evolus EV-to-FCF Historical Data
The historical data trend for Evolus's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Evolus's EV-to-FCF falls into.
Evolus's current Enterprise Value is $880.6 Mil.
Evolus's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus (NAS:EOLS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Evolus's share price for today is $13.42.
Evolus's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Evolus EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Evolus's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EOLS has been successfully added to your 